PASTE

Tome Biosciences Announces US Patent Issued for Integrase-Mediated Programmable Genomic Integration

Retrieved on: 
Tuesday, April 9, 2024
MD, MIT, Patent, Composition, PASTE, PGI, DNA, State, United States patent law

WATERTOWN, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Tome Biosciences, Inc., the programmable genomic integration (PGI) company, today announces the issuance of US Patent 11,952,571 for “Systems, Methods, and Compositions for Site-Specific Genetic Engineering Using Programmable Addition via Site-Specific Targeting Elements (PASTE)” by the US Patent and Trademark Office.

Key Points: 
  • WATERTOWN, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Tome Biosciences, Inc., the programmable genomic integration (PGI) company, today announces the issuance of US Patent 11,952,571 for “Systems, Methods, and Compositions for Site-Specific Genetic Engineering Using Programmable Addition via Site-Specific Targeting Elements (PASTE)” by the US Patent and Trademark Office.
  • This patent further protects Tome’s foundational PGI technology, integrase-mediated PGI (I-PGI), describes a system capable of performing I-PGI in a mammalian cell, and is exclusively licensed to Tome from MIT.
  • “Today’s issuance marks the fourth US patent granted that encompasses our I-PGI technology, strengthening our patent portfolio and broadening our exclusivity,” said Rahul Kakkar, MD, President and Chief Executive Officer of Tome.
  • Together, with US Patent 11,952,571, these patents cover methods and systems relating to the use of a Cas 9 nickase, reverse transcriptase and an integrase to integrate DNA sequences into programmed locations.

Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integration Platform

Retrieved on: 
Tuesday, December 12, 2023
Constellation, Entrepreneurship, Hospital, Genetic code, MIT, CMC, CRISPR, JD, PASTE, Brigham and Women's Hospital, DNA, MD, Doctor of Philosophy, Therapy, Investment, HR, Polaris Partners, Novo Nordisk, Novartis, Polaris, Patent, MorphoSys, Cas9, ARCH, ARCH Venture Partners, Gene expression, Bruker, Genetic heterogeneity, Gene, Merck, PGI, Genome, Enzyme, Fujifilm, Patient, GV, Intellia Therapeutics

Backed by leading biotech investors Andreessen Horowitz, ARCH, GV, Longwood, Polaris and others

Key Points: 
  • Backed by leading biotech investors Andreessen Horowitz, ARCH, GV, Longwood, Polaris and others
    WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Tome Biosciences , Inc., the programmable genomic integration company, has launched to usher in a new era of genomic medicines based on programmable genomic integration (PGI).
  • “PGI represents the maturation of editing technologies, breaking current barriers in genomic medicines discovery,” said Rahul Kakkar, MD, President and Chief Executive Officer.
  • “PGI is revolutionary in that we can finally reprogram the human genome with an elegance and efficiency previously unimaginable.
  • Tome has an exclusive license to the core PASTE technology, which includes granted US patent numbers 11,572,556, 11,827,881 and 11,834,658.